These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 1825813

  • 1. Androgen responses to acutely increased endogenous insulin levels in hyperandrogenic and normal cycling women.
    Elkind-Hirsch KE, Valdes CT, McConnell TG, Malinak LR.
    Fertil Steril; 1991 Mar; 55(3):486-91. PubMed ID: 1825813
    [Abstract] [Full Text] [Related]

  • 2. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F, Hatala DA, Speroff L.
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [Abstract] [Full Text] [Related]

  • 3. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS, Thompson DL.
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [Abstract] [Full Text] [Related]

  • 4. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide.
    Lasco A, Cucinotta D, Gigante A, Denuzzo G, Pedulla M, Trifiletti A, Frisina N.
    Eur J Endocrinol; 1995 Dec; 133(6):718-22. PubMed ID: 8548057
    [Abstract] [Full Text] [Related]

  • 5. Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion.
    Lanzone A, Fulghesu AM, Guido M, Fortini A, Caruso A, Mancuso S.
    Fertil Steril; 1992 Aug; 58(2):296-301. PubMed ID: 1321739
    [Abstract] [Full Text] [Related]

  • 6. Impact of overnight dexamethasone suppression on the adrenal androgen response to an oral glucose tolerance test in women with and without polycystic ovary syndrome.
    Buyalos RP, Geffner ME, Azziz R, Judd HL.
    Hum Reprod; 1997 Jun; 12(6):1138-41. PubMed ID: 9221990
    [Abstract] [Full Text] [Related]

  • 7. Leuprolide acetate-stimulated androgen response during female puberty.
    Hernandez MI, Martinez-Aguayo A, Cavada G, Avila A, Iñiguez G, Mericq V.
    Clin Endocrinol (Oxf); 2015 Aug; 83(2):205-11. PubMed ID: 25491105
    [Abstract] [Full Text] [Related]

  • 8. Insulin infusion acutely augments ovarian androgen production in normal women.
    Stuart CA, Nagamani M.
    Fertil Steril; 1990 Nov; 54(5):788-92. PubMed ID: 2146169
    [Abstract] [Full Text] [Related]

  • 9. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL, Lindheim SR, Lowre C, Ferin M, Gonzalez F, Berglund L, Carmina E, Sauer MV, Lobo RA.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [Abstract] [Full Text] [Related]

  • 10. Chronic hyperinsulinemia and the adrenal androgen response to acute corticotropin-(1-24) stimulation in hyperandrogenic women.
    Azziz R, Bradley EL, Potter HD, Parker CR, Boots LR.
    Am J Obstet Gynecol; 1995 Apr; 172(4 Pt 1):1251-6. PubMed ID: 7726265
    [Abstract] [Full Text] [Related]

  • 11. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome.
    Tropeano G, Lucisano A, Liberale I, Barini A, Vuolo IP, Martino G, Menini E, Dell'Acqua S.
    J Clin Endocrinol Metab; 1994 Feb; 78(2):305-9. PubMed ID: 8106616
    [Abstract] [Full Text] [Related]

  • 12. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease.
    Jialal I, Naiker P, Reddi K, Moodley J, Joubert SM.
    J Clin Endocrinol Metab; 1987 May; 64(5):1066-9. PubMed ID: 2951393
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
    Elkind-Hirsch KE, Anania C, Malinak R.
    J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level.
    Azziz R, Black VY, Knochenhauer ES, Hines GA, Boots LR.
    J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576
    [Abstract] [Full Text] [Related]

  • 17. The ovarian contribution to peripherally derived serum C19 conjugates.
    Matteri RK, Stanczyk FZ, Cassidenti DL, Paulson RJ, Lobo RA.
    J Clin Endocrinol Metab; 1992 Sep; 75(3):768-72. PubMed ID: 1387653
    [Abstract] [Full Text] [Related]

  • 18. Insulin resistance and secretion in polycystic ovarian disease.
    Bruno B, Poccia G, Fabbrini A.
    J Endocrinol Invest; 1985 Oct; 8(5):443-8. PubMed ID: 2934464
    [Abstract] [Full Text] [Related]

  • 19. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome.
    Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG.
    J Clin Endocrinol Metab; 1991 Jan; 72(1):83-9. PubMed ID: 1898744
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.